Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Wall Street on Friday erased all the gains made in the fledgling year, after a hotter-than-expected jobs report. Read more ...

Transmedics replaced its CFO in early December. Management also narrowed fourth-quarter guidance to the lower half of the previous range. Can Transmedics reaccelerate growth after this slowdown ...

TransMedics Group, Inc. (NASDAQ:TMDX), a leading player in the organ transplant technology sector with a market capitalization of $2.55 billion, has been making waves in the medical device ...

On Monday, Piper Sandler analyst Matt O'Brien maintained an Overweight rating and $90.00 price target on TransMedics Group (NASDAQ:TMDX), a company specializing in organ transplant technology.